|
|||||
|
|
Evaluation of Adjuvant Doxorubicin-Based Chemotherapy for the Treatment of Feline Mammary Carcinoma |
|
| Authors: | CJ McNeill KU Sorenmo FS Shofer L Gibeon AC Durham LG Barber JL Baez B Overley |
| Institution: | Department of Clinical Studies, Matthew J. Ryan Veterinary Hospital, University of Pennsylvania, Philadelphia, PA;;Department of Pathobiology, School of Veterinary Medicine, University of Pennsylvania, Philadelphia, PA;;Department of Clinical Sciences, Cummings School of Veterinary Medicine, Tufts University, North Grafton, MA;and;Center for Animal Referral and Emergency Services, Langhorne, PA |
| Abstract: | Background: Feline mammary carcinomas (FMC) are locally invasive and highly metastatic tumors. Because of the high metastatic potential, patients often are treated with adjuvant doxorubicin-based chemotherapy, but little data exist to evaluate the effect of this strategy. Hypothesis: Adjuvant doxorubicin-based chemotherapy improves outcome for FMC compared with surgery alone. Animals: Cats with naturally occurring, biopsy-confirmed FMC treated with either surgery alone (Sx) or with surgery plus adjuvant doxorubicin-based chemotherapy (Sx + Chemo). Methods: Retrospective cohort study. Clinical data were collected and compared to identify differences between groups. Outcome results were determined and compared. Prognostic factors for disease-free survival (DFS) and overall survival were evaluated. Results: Seventy-three cats were evaluated, of which 37 were in the Sx group and 36 in the Sx + Chemo group. No differences in clinical data were found between Sx and Sx + Chemo groups. Median DFS times for the Sx and Sx + Chemo groups were 372 and 676 days, respectively ( P = .15) and median survival times (ST) were 1,406 and 848 days, respectively ( P = .78). For cats that underwent a unilateral radical mastectomy, ST was significantly longer for the Sx + Chemo compared with the Sx group (1,998 versus 414 days, respectively; P = .03). Conclusions and Clinical Importance: This study did not find a benefit to adjuvant doxorubicin-based chemotherapy in cats with FMC. Additional studies are required to determine whether patient subgroups with negative prognostic factors may benefit from adjuvant chemotherapy. |
| Keywords: | Adriamycin Breast Cancer Cat Surgery |